KORU Medical Systems (NASDAQ:KRMD) CTO Buys $19,550.00 in Stock

KORU Medical Systems, Inc. (NASDAQ:KRMD) CTO Eric Schiller acquired 5,000 shares of the stock in a transaction dated Monday, May 18th. The shares were bought at an average price of $3.91 per share, with a total value of $19,550.00. Following the completion of the transaction, the chief technology officer directly owned 5,000 shares of the company’s stock, valued at $19,550. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

KORU Medical Systems Price Performance

Shares of KRMD opened at $4.10 on Friday. KORU Medical Systems, Inc. has a 1 year low of $2.63 and a 1 year high of $6.61. The company has a market capitalization of $188.31 million, a price-to-earnings ratio of -82.00 and a beta of 0.43. The business has a 50-day moving average of $4.18 and a 200-day moving average of $4.84.

KORU Medical Systems (NASDAQ:KRMD) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.01. KORU Medical Systems had a negative return on equity of 13.61% and a negative net margin of 5.27%.The company had revenue of $10.90 million during the quarter, compared to the consensus estimate of $10.90 million. As a group, sell-side analysts anticipate that KORU Medical Systems, Inc. will post -0.04 EPS for the current year.

Institutional Investors Weigh In On KORU Medical Systems

Several large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its stake in KORU Medical Systems by 52.1% in the third quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock valued at $39,000 after acquiring an additional 3,478 shares during the period. Lazard Asset Management LLC acquired a new stake in KORU Medical Systems in the second quarter valued at approximately $59,000. Acadian Asset Management LLC acquired a new stake in KORU Medical Systems in the first quarter valued at approximately $63,000. Arrowstreet Capital Limited Partnership acquired a new stake in KORU Medical Systems in the first quarter valued at approximately $79,000. Finally, Invesco Ltd. acquired a new stake in KORU Medical Systems in the second quarter valued at approximately $80,000. Institutional investors and hedge funds own 58.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Canaccord Genuity Group restated a “buy” rating and set a $6.00 price objective on shares of KORU Medical Systems in a research report on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Tuesday, April 21st. B. Riley Financial raised their price objective on KORU Medical Systems from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Finally, Wall Street Zen downgraded KORU Medical Systems from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, KORU Medical Systems has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.